$381 Million is the total value of Altium Capital Management LP's 124 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | New | APELLIS PHARMACEUTICALS INCput | $5,494,000 | – | 166,700 | +100.0% | 1.44% | – |
| KROS | New | KEROS THERAPEUTICS INC | $4,985,000 | – | 126,000 | +100.0% | 1.31% | – |
| XFOR | New | X4 PHARMACEUTICALS INC | $4,256,000 | – | 804,598 | +100.0% | 1.12% | – |
| AFMD | New | AFFIMED N V | $4,110,000 | – | 665,000 | +100.0% | 1.08% | – |
| BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $3,826,000 | – | 92,000 | +100.0% | 1.00% | – |
| ARCT | New | ARCTURUS THERAPEUTICS HLDGS | $3,822,000 | – | 80,000 | +100.0% | 1.00% | – |
| BBIO | New | BRIDGEBIO PHARMA INC | $3,703,000 | – | 79,000 | +100.0% | 0.97% | – |
| New | RENOVACOR INC | $3,519,000 | – | 388,845 | +100.0% | 0.92% | – | |
| ICAD | New | ICAD INC | $3,440,000 | – | 320,000 | +100.0% | 0.90% | – |
| TCON | New | TRACON PHARMACEUTICALS INC | $3,039,000 | – | 785,341 | +100.0% | 0.80% | – |
| New | DOUBLEDOWN INTERACTIVE CO LTads | $2,818,000 | – | 160,000 | +100.0% | 0.74% | – | |
| FLUX | New | FLUX PWR HLDGS INC | $2,652,000 | – | 521,972 | +100.0% | 0.70% | – |
| SRSA | New | SARISSA CAPITAL ACQUISITN COcl a | $2,219,000 | – | 225,000 | +100.0% | 0.58% | – |
| VQSLF | New | VIQ SOLUTIONS INC | $2,086,000 | – | 704,687 | +100.0% | 0.55% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $2,064,000 | – | 108,000 | +100.0% | 0.54% | – |
| New | GIGINTERNATIONAL1 INC | $1,974,000 | – | 200,000 | +100.0% | 0.52% | – | |
| New | CHAVANT CAPITAL ACQUISITN COordinary shares | $1,970,000 | – | 200,000 | +100.0% | 0.52% | – | |
| New | LAKESHORE ACQUISITION I CORPordinary shares | $1,966,000 | – | 200,000 | +100.0% | 0.52% | – | |
| ONCR | New | ONCORUS INC | $1,794,000 | – | 192,054 | +100.0% | 0.47% | – |
| LFMD | New | LIFEMD INC | $1,793,000 | – | 288,700 | +100.0% | 0.47% | – |
| CMRX | New | CHIMERIX INC | $1,744,000 | – | 281,790 | +100.0% | 0.46% | – |
| New | HILLMAN SOLUTIONS CORP | $1,694,000 | – | 142,000 | +100.0% | 0.44% | – | |
| VRPX | New | VIRPAX PHARMACEUTICALS INC | $1,305,000 | – | 271,846 | +100.0% | 0.34% | – |
| New | STRYVE FOODS INC | $1,070,000 | – | 200,000 | +100.0% | 0.28% | – | |
| PRQR | New | PROQR THRAPEUTICS N V | $1,046,000 | – | 125,000 | +100.0% | 0.27% | – |
| New | ARYA SCIENCES ACQUISITN CORP | $1,005,000 | – | 100,000 | +100.0% | 0.26% | – | |
| ALNA | New | ALLENA PHARMACEUTICALS | $963,000 | – | 1,067,886 | +100.0% | 0.25% | – |
| New | COLISEUM ACQUISITION CORP | $846,000 | – | 85,000 | +100.0% | 0.22% | – | |
| CERE | New | CEREVEL THERAPEUTICS HLDNG Iput | $611,000 | – | 20,700 | +100.0% | 0.16% | – |
| ALGS | New | ALIGOS THERAPEUTICS INC | $519,000 | – | 33,492 | +100.0% | 0.14% | – |
| New | RENOVACOR INC*w exp 99/99/999 | $501,000 | – | 731,561 | +100.0% | 0.13% | – | |
| CLBR | New | COLOMBIER ACQUISITION CORPcl a | $484,000 | – | 50,000 | +100.0% | 0.13% | – |
| SCYX | New | SCYNEXIS INC | $371,000 | – | 70,000 | +100.0% | 0.10% | – |
| KRYS | New | KRYSTAL BIOTECH INCcall | $303,000 | – | 5,800 | +100.0% | 0.08% | – |
| PSTX | New | POSEIDA THERAPEUTICS INC | $235,000 | – | 32,238 | +100.0% | 0.06% | – |
| New | RESERVOIR MEDIA INC*w exp 08/26/202 | $99,000 | – | 50,000 | +100.0% | 0.03% | – | |
| New | SURROZEN INC*w exp 08/01/203 | $94,000 | – | 82,233 | +100.0% | 0.02% | – | |
| New | LAKESHORE ACQUISITION I CORP*w exp 07/15/202 | $79,000 | – | 150,000 | +100.0% | 0.02% | – | |
| SRSAW | New | SARISSA CAPITAL ACQUISITN CO*w exp 10/23/202 | $75,000 | – | 75,000 | +100.0% | 0.02% | – |
| New | CHAVANT CAPITAL ACQUISITN CO*w exp 99/99/999 | $72,000 | – | 150,000 | +100.0% | 0.02% | – | |
| New | GIGINTERNATIONAL1 INC*w exp 04/19/202 | $37,000 | – | 50,000 | +100.0% | 0.01% | – | |
| CLBRWS | New | COLOMBIER ACQUISITION CORP*w exp 99/99/999 | $9,000 | – | 16,666 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-11-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FAT BRANDS INC | 12 | Q3 2023 | 0.6% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.9% |
| BELLUS HEALTH INC NEW | 10 | Q1 2023 | 4.7% |
| XTANT MED HLDGS INC | 10 | Q3 2023 | 5.1% |
| IVERIC BIO INC | 10 | Q1 2023 | 2.3% |
| MYRIAD GENETICS INC | 10 | Q1 2023 | 2.3% |
| HARBOR CUSTOM DEVELOPMENT IN | 10 | Q3 2023 | 0.1% |
| CRINETICS PHARMACEUTICALS IN | 9 | Q3 2023 | 4.1% |
| CTI BIOPHARMA CORP | 9 | Q1 2023 | 2.6% |
| POLISHED COM INC | 9 | Q2 2023 | 3.4% |
View Altium Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Marpai, Inc. | April 26, 2023 | 1,805,327 | 6.2% |
| Astria Therapeutics, Inc. | February 14, 2023 | 1,355,372 | 5.0% |
| HyreCar Inc. | February 14, 2023 | 1,688,120 | 5.6% |
| Muscle Maker, Inc. | February 14, 2023 | 2,888,085 | 5.0% |
| NeuroBo Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| PALISADE BIO, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| 1847 Goedeker Inc. | February 14, 2022 | 6,103,824 | 5.0% |
| BioRestorative Therapies, Inc. | February 14, 2022 | 200,000 | 5.0% |
| BriaCell Therapeutics Corp. | February 14, 2022 | 900,000 | 4.7% |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | February 14, 2022 | 363,000 | 5.0% |
View Altium Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-08 |
| SC 13G | 2024-02-21 |
| SC 13G | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Altium Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.